J&J Has Competition in Race for New Blockbuster Sex Pill

(MoneyWatch)  Johnson & Johnson has a competitor for Priligy, its anti-premature ejaculation pill, the LA Times reports:

Dr. Michael G. Wyllie and his colleagues at Plethora Solutions Ltd. in London have developed an anesthetic spray called PSD502, or Tempe. A combination of lidocaine and prilocaine, it is absorbed only by the glans penis...

Time to orgasm increased a mean of 6.3 times in the men using the spray, compared with a 1.7-fold increase in men using the placebo.

BNET previously noted J&J's increasing interest in sex-related treatments back in February. J&J, via Janssen Korea, filed for approval for Priligy in Korea last week. It could be available there in Q3 or Q4. The JoonAng Daily reports:

Currently, it's available in only Finland, Sweden, Austria, Portugal and Germany. It has not been approved in the United States.

[with Priligy] ejaculation time increased from an average of 62 seconds to four minutes for 30 milligrams of Priligy, and to 4.5 minutes for 60 milligrams.

... Side effects included drowsiness, insomnia and nausea.

Priligy has been rejected by the FDA in the U.S. in part because it's actually an antidepressant (dapoxetine) with a short active life, and its effect on sex was originally noted as a side effect.

The JoonAng Daily also reports this priceless piece of information about the development of international standard for PE:

Although there is no standard to define the time of premature ejaculation, the third International Consultation on Sexual Medicine will likely set it at one minute.

• Previously:
• With Premature Ejaculation Pill, J&J Takes Another Step Into the Sex Biz

--

MoneyWatch Poll: How Has the Financial Crisis Affected You?